(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.45%) $83.47
(-1.16%) $1.619
(-0.01%) $2 346.90
(0.80%) $27.47
(0.34%) $925.20
(-0.05%) $0.934
(-0.08%) $11.02
(-0.07%) $0.800
(0.00%) $92.17
Live Chart Being Loaded With Signals
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications...
Stats | |
---|---|
本日の出来高 | 1 387.00 |
平均出来高 | 6 543.00 |
時価総額 | 232.27M |
EPS | £0 ( 2024-03-24 ) |
Last Dividend | £62.00 ( 2023-04-06 ) |
Next Dividend | £0 ( N/A ) |
P/E | 27.30 |
ATR14 | £18.19 (0.41%) |
Bioventix PLC 財務諸表
Annual | 2022 |
収益: | £12.82M |
総利益: | £11.86M (92.53 %) |
EPS: | £1.610 |
FY | 2022 |
収益: | £12.82M |
総利益: | £11.86M (92.53 %) |
EPS: | £1.610 |
FY | 2022 |
収益: | £11.72M |
総利益: | £11.01M (93.94 %) |
EPS: | £1.470 |
FY | 2021 |
収益: | £10.93M |
総利益: | £10.11M (92.52 %) |
EPS: | £1.303 |
Financial Reports:
No articles found.
Bioventix PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£0 (N/A) |
£26.00 (N/A) |
£0 (N/A) |
£62.00 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | £14.40 | 2014-10-16 |
Last Dividend | £62.00 | 2023-04-06 |
Next Dividend | £0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | £610.50 | -- |
Avg. Dividend % Per Year | 1.28% | -- |
Score | 4.07 | -- |
Div. Sustainability Score | 9.02 | |
Div.Growth Potential Score | 6.87 | |
Div. Directional Score | 7.94 | -- |
Year | Amount | Yield |
---|---|---|
2014 | £14.40 | 2.42% |
2015 | £32.60 | 4.47% |
2016 | £36.50 | 2.89% |
2017 | £60.00 | 4.44% |
2018 | £80.00 | 3.23% |
2019 | £77.00 | 2.51% |
2020 | £89.00 | 2.68% |
2021 | £81.00 | 1.82% |
2022 | £78.00 | 2.29% |
2023 | £62.00 | 1.50% |
2024 | £0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SGE.L | Dividend Knight | 2023-06-01 | Semi-Annually | 32 | 1.64% | |
IEML.L | No Dividend Player | 2023-08-10 | Insufficient data to determine frequency | 2 | 1.30% | |
BME.L | Dividend King | 2023-06-29 | Semi-Annually | 11 | 4.74% | |
XPP.L | Dividend Knight | 2023-09-07 | Quarterly | 18 | 1.72% | |
NWOR.L | Dividend Knight | 2023-06-01 | Insufficient data to determine frequency | 2 | 0.88% | |
ENT.L | Dividend Junior | 2023-08-17 | Annually | 19 | 0.58% | |
SRE.L | Dividend Knight | 2023-07-13 | Semi-Annually | 18 | 2.26% | |
JGGI.L | Dividend King | 2023-08-31 | Quarterly | 53 | 2.32% | |
BYIT.L | Dividend Knight | 2023-07-20 | Annually | 4 | 0.95% | |
PRSR.L | Dividend Knight | 2023-08-10 | Quarterly | 7 | 2.62% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.637 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.659 | 1.200 | 10.00 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.738 | 1.500 | 2.92 | 4.37 | [0.1 - 1] |
payoutRatioTTM | 0.915 | -1.000 | 0.847 | -0.847 | [0 - 1] |
currentRatioTTM | 7.04 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 6.69 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.22 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.562 | 2.00 | 9.48 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.561 | 2.00 | 9.22 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.928 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.789 | 1.000 | 10.00 | 10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 1.034 | 0.800 | 6.44 | 5.15 | [0.5 - 2] |
Total Score | 9.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 26.80 | 1.000 | 7.39 | 0 | [1 - 100] |
returnOnEquityTTM | 0.738 | 2.50 | 5.45 | 4.37 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.561 | 2.00 | 9.48 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.55 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.562 | 2.00 | 9.48 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.915 | 1.500 | 0.847 | -0.847 | [0 - 1] |
pegRatioTTM | 281.43 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.600 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 6.87 |
Bioventix PLC
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。